Answer first
Medical cannabis changed daily life for some patients and did little for others. Results track three things: the condition, the dose, and the product form. Evidence is strongest for chronic pain, chemotherapy-induced nausea and vomiting, and muscle spasticity from multiple sclerosis. For most other qualifying conditions, state programs hold patient reports, not controlled trials.
Medical Cannabis Patient Video Testimonials: Has Convenience Become the Deciding Factor?
Where the evidence is strongest
A 2017 review by the National Academies of Sciences, Engineering, and Medicine weighed more than 10,000 abstracts. It found substantial or conclusive evidence for those three uses and limited or no evidence for several others.
real medical cannabis patient stories
Chronic pain
Chronic pain sits on the qualifying condition list in every medical state. It accounts for the largest share of registered patients in state reports, at 60 percent or more in several states. Patients describe changes in sleep and function more than changes in pain scores.
medical marijuana patient reviews by condition
Nausea and spasticity
The FDA approved dronabinol, a synthetic THC, in 1985 for chemotherapy-induced nausea and vomiting. Epidiolex, a purified CBD liquid, won approval in 2018 for two severe childhood epilepsy syndromes and in 2020 for tuberous sclerosis complex. These are the only cannabis-derived drugs with FDA approval. Median seizure reductions in the pivotal trials ran from 39 percent to 44 percent, against 13 percent to 22 percent for placebo.
What patients report
Surveys in state programs show the same three complaints improve most: pain, sleep, and appetite. Anxiety appears in patient reports but the trial base is thin. Opioid claims get the most attention. Some patients report lower opioid doses after they start cannabis. Randomized trials have not shown a mortality benefit, and reviews do not agree on a dose reduction effect.
What convenience changed
Access changed the patient experience as much as the drug. Ten years ago a patient drove to one dispensary, waited, and paid cash. Today many states allow delivery, curbside pickup, and online renewal of a medical card.
Product labels changed too. A tincture now lists milligrams of THC and CBD per milliliter. Metered inhalers list milligrams per puff. That lets a patient repeat a dose instead of guessing.
Convenience carries a cost. Delivery and online renewal lower the barrier for people with mobility limits. They also lower the barrier for people with no medical need. Regulators in several states cite this tension when they tighten rules.
Costs and limits
No US health plan covers cannabis flower or edibles. Patients pay cash. Monthly out-of-pocket spending runs from about $100 to $400 based on dose. That compares with a generic opioid at a few dollars per month.
Side effects include dizziness, dry mouth, and drowsiness. Cannabis impairs driving. About 3 in 10 people who use cannabis develop cannabis use disorder, per the National Institute on Drug Abuse.
What is not known
No large randomized trial has tested smoked flower against placebo for chronic pain. Program counts and qualifying condition lists change each year, so any number here has a shelf life.